Evidence map›Paper›PMID 42012738›Full record

ArticleAnnals of surgical oncology2026

Exploring the Associations and Mechanisms Between Antihypertensive Drugs and Urological Tumors: Insights from a Mendelian Randomization Study.

Kun Wang, Feixiang Yang, Wei Dai, Xiangyu Zhang, Yuanyuan Wang, Tianrui Liu, Hao Li, Andong Cheng, Jialin Meng, Yiding Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kun Wang *Department of Urology, Institute of Urology & Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, People's Republic of China.
Feixiang Yang *Department of Urology, Institute of Urology & Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, People's Republic of China.
Wei Dai *Department of Urology, (The Affiliated Wuhu Hospital of East China Normal University, The Second People's Hospital of Wuhu City), Wuhu, People's Republic of China.
Xiangyu ZhangFirst School of Clinical Medicine, Anhui Medical University, Hefei, People's Republic of China.
Yuanyuan WangFirst School of Clinical Medicine, Anhui Medical University, Hefei, People's Republic of China.
Tianrui LiuSecond School of Clinical Medicine, Anhui Medical University, Hefei, People's Republic of China.
Hao LiDepartment of Urology, Institute of Urology & Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, People's Republic of China.
Andong ChengDepartment of Urology, Institute of Urology & Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, People's Republic of China.
Jialin MengDepartment of Urology, Institute of Urology & Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, People's Republic of China. mengjialin@ahmu.edu.cn.
Yiding ChenDepartment of Urology, Institute of Urology & Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, People's Republic of China. xytcyd@163.com.

Funding

College Students' Innovation and Entrepreneurship Training Program of Anhui Medical University X202310366062Early scientific training program of Anhui Medical University 2022-ZQKY-194
6 · The paper itself

Abstract

backgroundHypertension is a risk factor for urological tumors. However, the impact of antihypertensive drugs on these tumors is unclear.

methodsWe used summary statistics from genome-wide association studies (GWASs) of urological tumors, along with expression data for antihypertensive drug target genes from GWASs and eQTLGen. We employed two-sample Mendelian randomization and summary-based Mendelian randomization (SMR) to assess the associations between antihypertensive drugs, target genes, and urological tumors. Two-step MR analysis was performed to investigate the mediating role of protein in these associations. We further verified this finding through co-localization analysis and differential expression analysis. We also mined the US Food and Drug Administration Adverse Event Reporting System database and Phenome-Wide Association Study to study the adverse effects of antihypertensive drugs and their target genes.

resultsAngiotensin-II receptor antagonist, PSDs, and aldosterone antagonists increase the risk of testicular cancer. Angiotensin-converting enzyme inhibitors decrease the risk for prostate cancer. Genetically, PPARG increases the risk of testicular cancer, as confirmed by SMR (PPARG: P = 2.1×10

conclusionAntihypertensive drugs and target genes are significant in the development of urological tumors and crucial for the development of treatment strategies.

Indexed as

Antihypertensive AgentsHypertensionUrologic NeoplasmsAngiotensin Receptor AntagonistsDiuretics, Potassium SparingGenome-Wide Association StudyHumansMaleMendelian Randomization AnalysisMineralocorticoid Receptor AntagonistsPolymorphism, Single NucleotidePPAR gammaTesticular NeoplasmsAngiotensin Receptor AntagonistsAntihypertensive AgentsDiuretics, Potassium SparingMineralocorticoid Receptor AntagonistsPPAR gammaAntihypertensive drugsFDA adverse event reporting systemMendelian randomizationPhenome-wide association studyUrological tumors

Identifiers

PMID42012738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.